Planegg, Germany
NEOsphere Biotechnologies GmbH, founded in 2022 and headquartered in Germany, is at the forefront of the biotechnology industry. Its slogan, "From Library to Lead. Proteomics Guided Induced Proximity Drug Discovery.", encapsulates its mission to transform drug discovery.
The company expertly combines world-class mass spectrometry with data analysis to create comprehensive pipelines targeting novel degrader candidates. Its platform's key differentiator is its agnosticism to both targets and E3 ligases, allowing for unbiased and high-throughput screening of degrader libraries. This innovation makes the previously undruggable target space accessible, facilitated by extensive expert data analysis.
NEOsphere recently secured an Early VC investment on 01 February 2024, with support from Ventura BioMed Investors and Voima Ventures, positioning itself as a promising participant in the targeted protein degradation landscape with its cutting-edge technologies and strong investment backing.
